• Xenetic Biosciences announced the first patient was dosed in a study combining systemic DNase with CAR T-cell therapy for large B-cell lymphoma.
• The 12-patient study at Tel Aviv Sourasky University Medical Center marks the technology’s first clinical evaluation alongside CAR T-cell therapy.
• Researchers will assess whether DNase improves treatment response by helping CAR T cells expand and persist.
• Clinical outcomes will be evaluated during follow-up, including survival at 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610150846ACCESSWRNAPR_____1236901) on October 15, 2026, and is solely responsible for the information contained therein.